Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00597584 · ClinicalTrials.gov registry record · Phase 3
Safety & Efficacy of Peginesatide for Maintenance Treatment of Anemia in Participants With Chronic Kidney Disease on Hemodialysis
A Phase 3 study, sponsored by Affymax.
- Completed
- Registry status
- Phase 3
- Development phase
- 823
- Enrollment target
NCT00597584 is a Phase 3 study that has completed, run by Affymax. The registered enrollment target is 823 participants.
The verdict
NCT00597584, a Phase 3 study, has completed, sponsored by Affymax.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 823 participants
- Enrollment target
Study Summary
The purpose of this study was to evaluate the safety and efficacy of peginesatide in the maintenance treatment of anemia in participants on dialysis.
Interventions
- DRUG peginesatide
- DRUG Epoetin alfa or Epoetin beta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 823 participants |
| Start Date | 2007-10 |
| Est. Completion | 2010-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00597584
The ClinicalTrials.gov registry entry for NCT00597584 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 823 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Affymax, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which peginesatide is the first listed.
NCT00597584 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00597584 about?
NCT00597584 is a clinical study titled "Safety & Efficacy of Peginesatide for Maintenance Treatment of Anemia in Participants With Chronic Kidney Disease on Hemodialysis". The purpose of this study was to evaluate the safety and efficacy of peginesatide in the maintenance treatment of anemia in participants on dialysis.
What is the current status of trial NCT00597584?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 823 participants. The study started on 2007-10. Estimated completion is 2010-01.
What interventions are being tested in trial NCT00597584?
The interventions under investigation include: peginesatide (DRUG), Epoetin alfa or Epoetin beta (DRUG).
Who is sponsoring clinical trial NCT00597584?
This trial is sponsored by Affymax, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.